Cytomegalovirus (CMV) in transplant patients is treated primarily with antiviral medications, either given preventively starting soon after transplant or triggered by rising viral levels detected through regular blood monitoring. The approach depends on the type of transplant, the CMV risk profile of the donor and recipient, and whether the infection responds to first-line drugs. Treatment can range from a straightforward course of oral antivirals to complex regimens involving newer targeted therapies for resistant infections.
Two Main Prevention Strategies
Transplant centers use one of two broad strategies to keep CMV from causing serious disease. The first is prophylaxis: giving antiviral medication to all at-risk patients starting within days of transplant, typically for about 100 days. This blanket approach is common for high-risk patients, particularly when the organ donor previously had CMV but the recipient did not. In that scenario, the recipient has no pre-existing immune memory against the virus and is especially vulnerable.
The second strategy is preemptive therapy. Instead of treating everyone, the transplant team monitors viral levels in the blood weekly using a DNA test and only starts antiviral medication when the virus begins replicating above a certain threshold. In bone marrow transplant recipients, treatment may be triggered at viral loads as low as 135 IU/mL. Research from the Fred Hutchinson Cancer Center found that starting treatment at these lower levels shortened both the time to clear the virus and the total duration of therapy compared to waiting for higher levels. For solid organ transplant recipients, the exact threshold varies by center and organ type, but the principle is the same: catch it early, treat it fast.
Neither strategy is universally superior. Prophylaxis exposes more patients to drug side effects but catches nearly all cases. Preemptive therapy spares many patients from unnecessary medication but requires reliable weekly monitoring and fast turnaround on lab results.
First-Line Antiviral Treatment
The standard treatment for active CMV infection in transplant patients is an antiviral that blocks the virus from copying its DNA. For patients who can take pills and absorb them reliably, an oral formulation is the usual choice. For patients who are critically ill, vomiting, or have gut complications that interfere with absorption, an intravenous version of the same drug is used instead.
Dosing is not one-size-fits-all. The amount given depends heavily on kidney function because the drug is cleared through the kidneys. In adults, the dose is adjusted based on creatinine clearance, a measure of how well the kidneys filter waste. In children, a dosing formula factors in both body surface area and kidney function to match the drug exposure levels known to be safe and effective in adults. Getting the dose right matters: too little allows the virus to persist and potentially develop resistance, while too much increases the risk of the drug’s main side effect, which is suppression of bone marrow. This can lower white blood cell counts, making an already immunosuppressed patient even more vulnerable to infections.
Treatment typically continues until the virus is no longer detectable in the blood on two consecutive tests. Throughout treatment, viral levels are checked weekly to confirm the drug is working.
Adjusting Immunosuppression
Because transplant patients take medications that deliberately weaken the immune system to prevent organ rejection, one of the most important parts of CMV treatment is dialing back that immunosuppression. The goal is to give the patient’s own immune system more room to fight the virus without triggering rejection of the transplanted organ. This is a delicate balance. The transplant team typically reduces or temporarily stops certain immune-suppressing drugs while closely watching for signs of rejection through blood work and, when needed, biopsies of the transplanted organ.
When First-Line Treatment Fails
In some cases, the virus does not respond to standard antiviral therapy. This can happen for two reasons: the infection is refractory (it simply is not responding despite adequate drug levels) or the virus has developed genetic resistance. Resistance typically arises through mutations in two specific genes in the CMV genome. Mutations in one gene affect how the virus activates the drug, while mutations in the other affect the enzyme the drug targets directly. The second type is more concerning because it can cause resistance to multiple antiviral drugs simultaneously. When resistance is suspected, sequencing these genes from a blood sample can identify the specific mutations and guide the choice of alternative therapy.
The traditional second-line options for resistant CMV carry significant toxicity. The most commonly used alternative causes kidney damage in roughly half of patients by the end of treatment, based on a study of 39 transplant recipients. Nearly all patients receiving this drug need intravenous fluids before each dose to protect the kidneys. It can also cause dangerous electrolyte imbalances and painful ulcers. A third older option poses similar kidney risks along with eye inflammation. Because of these toxicities, doses frequently need to be reduced during treatment, and in some cases, patients receive doses too low to clear the virus, leading to treatment failure.
Maribavir for Refractory Infections
A newer option approved by the FDA has changed the outlook for patients whose CMV does not respond to conventional drugs. Maribavir (brand name Livtencity) works through a completely different mechanism than older antivirals. It blocks a specific viral enzyme involved in assembling and releasing new virus particles from infected cells. It is approved for adults and children aged 12 and older (weighing at least 35 kg) with CMV infection after transplant that has not responded to treatment with any of the older antiviral options, whether or not genetic resistance has been confirmed.
The drug is taken as two tablets twice daily by mouth, with or without food. Its side effect profile is considerably more manageable than the older second-line agents. It does not carry the same kidney damage risk, which is particularly important for transplant patients whose kidney function may already be compromised by other medications or by the transplant itself. The most common side effect is a taste disturbance, which, while unpleasant, is far less dangerous than the organ toxicity associated with older alternatives.
CMV Immune Globulin as Add-On Therapy
In certain situations, transplant teams add CMV-specific antibodies given intravenously alongside antiviral drugs. This is not a routine part of treatment but is considered in specific scenarios: when the virus is resistant to standard drugs, when the patient has severe disease such as CMV pneumonia or eye involvement, when viral levels continue rising above 100,000 IU/mL despite antiviral treatment, or when the patient has unusually low antibody levels (hypogammaglobulinemia). Heart and lung transplant recipients, who tend to have higher rates of drug-resistant CMV than other organ recipients, are the group most likely to receive this addition. Some centers also use it when a patient cannot tolerate standard antivirals due to side effects, providing a bridge therapy with a different safety profile.
Newer Preventive Options
Letermovir, a drug originally approved for CMV prevention after bone marrow transplant, is being used at some centers for solid organ transplant recipients as well. It works through a different viral target than traditional antivirals and causes less bone marrow suppression, making it an attractive option for patients who cannot tolerate standard prophylaxis. One important practical consideration: letermovir interacts significantly with tacrolimus, one of the most commonly used anti-rejection drugs. When letermovir is started, the tacrolimus dose typically needs to be cut by 40 to 50 percent, with close monitoring of blood levels to prevent tacrolimus toxicity. Resistance to letermovir involves mutations in a third CMV gene, which can be tested alongside the traditional resistance genes when breakthrough infection occurs.
Monitoring During and After Treatment
Weekly blood testing for CMV DNA is the backbone of management throughout treatment. These tests track whether the viral load is falling, stable, or rising, which directly informs decisions about continuing, changing, or stopping therapy. If the viral load is not declining after two weeks of appropriate treatment, the team will consider resistance testing and may switch medications.
Monitoring does not stop when the virus clears. CMV has a tendency to reactivate, especially in the first year after transplant when immunosuppression is at its highest. After completing treatment, patients typically continue with regular viral load checks, often weekly at first and then at longer intervals as time passes without recurrence. A second episode of CMV is treated similarly to the first, though the threshold for investigating drug resistance is lower, and the team may be more aggressive about reducing immunosuppression or adding immune globulin.